Genomic Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Genomic Biomarkers Market is Segmented by Indication (Oncology, Cardiovascular, Neurological Diseases, Renal Disorders, and Others), End User, and Geography.

Market Snapshot

image 1_genomics
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global genomic biomarkers market is expected to witness a CAGR of 9.2% over the forecast period. The rising burden of chronic diseases (cardiovascular diseases, cancer, strokes, and arthritis), high demand for minimally invasive procedures, technological advancements, development in R&D, and the infrastructure for data sharing and the demand for personalized medicines are expected to drive the growth during the forecast period. Technologies such as Gene Expression Profiling (microarray) and Next-Generation Sequencing (NGS) are currently the leading advances in this market segment. According to the World Health Organization’s estimation in 2018, nearly 1 out of every 6 death is due to cancer followed by cardiovascular diseases, which accounts for the number one cause of death in the world. In August 2020, GeneCentric Therapeutic announced its entry into a research collaboration with Janssen Research & Development, LLC around an RNA-Based genomic biomarker, to develop novel non- invasive bladder cancer (NMIBC). According to a 2015 publication by the United States Food and Drug Administration (USFDA), they have undertaken several initiatives to initiate the use of genomic biomarkers in the development of medicinal products. However, high cost, complex development process, stringent government regulations and lack of standardized means to validate the marker may impose few challenges in the growth of genomic biomarkers market.

Scope of the Report

Genomic biomarkers are Deoxyribonucleic acid (DNA) and Ribonucleic acid (RNA) characteristics, that are used as an indicator of diagnosis, disease characterization, and therapy selection. It reflects biological and pathogenic processes and response to therapeutic or other intervention. They are variant in the DNA code that alone or in combination enables early detection of disease by predicting its risk and improves patient treatment by monitoring the outcomes.

By Indication
Cardiovascular diseases
Neurological diseases
Renal Disorders
By End User
Diagnostic Centers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oncology Segment is Expected to Dominate the Market in The Forecast Period

Based on the indication, the oncology segment is expected to lead the market growth. Oncology biomarkers are expected to show significant growth due to an increase in the prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, push-in target therapies, technological advancements, and reliability on oncology biomarkers drive the growth of the market. As per the 2018 estimation by the International Agency for Research on Cancer (IRAC), the global burden is expected to reach 27.5 million new cancer cases by 2040. The factors responsible for the growing burden include smoking, unhealthy lifestyle, and lack of physical activities. The burden may probably further increase beyond IRAC estimation, thus increasing the opportunities in terms of the patient pool and customized medicines. Further, such factors escalating, the biopharmaceutical companies are expected to have higher priorities in relation to the expansion of products under the oncology category, thus, expected to boost the growth of this market, over the forecast period.


North America is Expected to Lead the Market

In terms of geography, North America is expected to hold the highest market share in the forecast period. The major reasons accelerating the market in this region includes developed healthcare infrastructure, favorable government policies, and huge research grants. The United States is by far leading the market in North America and continues to do so even in the forecast period. For instance, in August 2020 Cancer Genetics Inc., a US-based company signed a definitive merger agreement with StemoniX, a private company to accelerate the development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the combined company. Such engagements in extensive R&D activities, advanced technologies, and substantial funding by the government as well as by the private organizations project the array of growth in the United States. Similar trends can be expected over the forecast period.

geno geoooooooooooooooo.jpg

Competitive Landscape

The Genomic Biomarkers Market is highly competitive owing to the presence of large number of competitors. To sustain and increase footprints in such a competitive landscape, major players are adopting a lot of strategies such as product innovations, expansions, technology upgrades, investments in R&D as well as mergers and acquisitions. In 2018, BioMrieux SA completed the acquisition of Astute Medical to have access to biomarkers in the product pipeline of Astute Medical.

Major players currently in the market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics Inc, Eurofins Scientific, QIAGEN etc.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevelance of Chronic Diseases

      2. 4.2.2 Technological Adancements in Molecular Biology, Genetics, Omics Technologies and Bioinformatics

      3. 4.2.3 Growing Awareness about Genomics Biomarkers

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Standardized Means for Validating the Marker

      2. 4.3.2 Stringent Government Regulations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Indication

      1. 5.1.1 Oncology

      2. 5.1.2 Cardiovascular diseases

      3. 5.1.3 Neurological diseases

      4. 5.1.4 Renal Disorders

      5. 5.1.5 Others

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Diagnostic Centers

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Almac Group

      2. 6.1.2 Bio-Rad Laboratories Inc.

      3. 6.1.3 Cancer Genetics Inc

      4. 6.1.4 Eurofins Scientific

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Genomic Health

      7. 6.1.7 Myriad Genetics Inc

      8. 6.1.8 QIAGEN

      9. 6.1.9 Thermo Fisher Scientific Inc

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Genomic Biomarkers Market market is studied from 2018 - 2026.

The Genomic Biomarkers Market is growing at a CAGR of 9.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Thermo Fisher Scientific Inc. , F. Hoffmann-La Roche Ltd , Myriad Genetics Inc, Eurofins Scientific , QIAGEN are the major companies operating in Genomic Biomarkers Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!